An experimental meningitis vaccine appears to generate more potent immunity than the version now available in young people who suffer most from the disease, researchers reported Monday. Previous research shows the Novartis vaccine, called Menveo, also works in young infants, who are not protected by the current vaccine. BETTER LIFE: Health news and wellness tips "It has a great deal of potential in that age group," says Keith Reisinger, medical director of Primary Physicians Research Inc., the for-profit clinical trials organization that carried out the Novartis study.